U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07379918) titled 'Real-life Evaluation of Endopredict(R) in Early HR+/HER2- Breast Cancer' on Jan. 23.
Brief Summary: EndoPredict is a genomic signature used to determine the 10-year risk of recurrence in early HR+/HER2- breast cancers classified as of intermediate risk according to conventional clinical and pathological criteria, and to guide the adjuvant treatment decision: hormone therapy alone or hormone therapy and chemotherapy.
Since 2016, french laboratories performing the Endopredict test, included prospectively analyzed tumors in the SiMoSein registry with data collection : age, tumor size, lymph node status, histology, grade, HR and HER2 IH...